Truqap or capivasertib is a serine/threonine kinase inhibitor. It inhibits the enzymatic activity of serine/threonine kinase isoforms AKT 1, 2, and 3, which play a role in proliferation of cancer cells with mutations in PIK3CA, AKT1 or PTEN genes. Thus, it aids in reducing the growth of cancer cells.
It is indicated, in combination with fulvestrant (anti-oestrogen medicine) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-mutations (as detected by an FDA-approved test) following progression on at least one endocrine-based regimen like aromatase inhibitor (to reduce estrogen levels) in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Common adverse reactions to treatment with capivasertib include diarrhea, cutaneous adverse reactions, increased random glucose or hyperglycemia, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased leukocytes, increased triglycerides, decreased neutrophils, increased creatinine, vomiting and stomatitis.
Capivasertib may cause fetal harm. Hence, it is advised to avoid use in pregnancy. Confirm negative pregnancy status before starting treatment. Use of effective contraception during treatment and for 4 months after the last dose, is advised.
Do not breastfeed during treatment due to potential for serious harm to infants. Not established as safe or effective for pediatric use. No efficacy differences in those ≥65 years, but higher rates of adverse reactions and treatment modifications. No dose changes needed for mild/moderate renal or hepatic impairment. Not studied in severe impairment. Monitor moderate hepatic cases closely.
Pricing and Availability
Capivasertib is not registered for commercial sale in India and is therefore unavailable through standard pharmacies or local distributors.
As this is a prescription-only therapy, pricing details for capivasertib are provided upon request, following the submission of valid medical documents and a doctor’s prescription. For the latest pricing information and procurement assistance, patients or caregivers are encouraged to contact our team directly.
The cost of capivasertib in India may vary depending on several factors, including supplier source, market conditions, regulatory requirements, and international availability. Additional elements such as shipping costs, documentation fees, origin country, and currency exchange rates may also influence the final price.
Fluctuations in GST or local taxes, as well as adjustments in manufacturer pricing policies, can further affect total cost. We facilitate patient access to capivasertib in India under the Named Patient Supply (NPS) program, ensuring full legal and regulatory compliance. Our dedicated support team oversees the process from document verification to final delivery, ensuring safety and transparency at each stage.
Access Pathway
Since capivasertib is not commercially licensed in India, it can only be accessed through the Named Patient Import Program (NPIP). Using this pathway, we assist patients in obtaining unregistered medicines like capivasertib under the NPIP framework, ensuring the process follows all applicable import regulations.
Through this program, we provide guidance on the necessary steps, documentation, and regulatory requirements, helping patients access the treatment they need safely and efficiently. Our support ensures that the import process is smooth while remaining fully compliant with Indian laws.
Capivasertib or Truqap is available as 64 film coated tablets in one bottle, where each tablet contains 60mg or 200mg.
Import Process
1) Submit Your Request
The patient or caregiver starts by sending a request that includes basic treatment details and a valid prescription.
2) Fill Form 12A
Next, Form 12A is completed and submitted along with a prescription from a Registered Medical Practitioner (RMP).
3) Document Review
All medical and ID documents are checked to make sure the patient is eligible to import the medicine for personal use.
4) Get Approval
Once the Drugs Controller General of India (DCGI) approves the request, the import process can move forward as per the prescription.
5) Source the Medicine
Our team works with trusted international suppliers to get the required medicine at the best possible price, ensuring it is authentic and compliant.
6) Delivery to Your Address
After final clearance, customs and logistics are handled to ensure the medicine is safely and quickly delivered to the patient’s address in India.
Required Documentation
To import capivasertib in India, patients must provide:
-
Valid prescription from a doctor, mentioning the medicine name, dosage, duration of treatment, and diagnosis.
-
Recent medical history and supporting lab reports, preferably issued within the last three months.
-
Government-issued ID and proof of residence of the patient.
-
Import permit, if required.
Orders are finalized only upon receipt of all required documents and verification of medical eligibility. Once the import permit is approved, the licensed supplier arranges shipment of capivasertib from approved international sources such as the United States, Canada, Europe, or Australia.
We ensure that every import is conducted safely, ethically, and in full regulatory compliance. Our organization provides nationwide delivery through verified suppliers, guaranteeing product authenticity and complete transparency in pricing and process. All prescriptions are reviewed and dispensed by registered pharmacists prior to delivery.
If you are looking for more detailed information about this medication, its availability, or guidance with the import procedure, our team is here to support you every step of the way. For personalised assistance, pricing details, and expert help in sourcing the medicine safely and legally, please visit
247qualitymeds.com. We are committed to helping patients access the treatment they need with confidence and ease.
